当Actavis同意11月17日收购其他557亿美元的药品司布·艾历师时，它完成了迅速转型进入全球十大药品球员，其中一个名字品牌。其中：Botox，allergan在投资组合中的宝石。Actavis友好的收购，该友好收购位于新泽西州帕斯佩瓦尔·特洛伊丘陵山，是最新的浪潮，正在重塑制药行业的系列和跨境税务交易。
自2012年底以来，Actavis已经走了很长的路，当时通过购买瑞士竞争对手的目前的名字。Before that the U.S. company, formerly known as Watson Pharmaceuticals, was a top five manufacturer of generic drugs, but “it wasn’t viewed as anything special,” says Tim Chiang, a senior analyst who covers the pharmaceuticals sector at CRT Capital Group in Stamford, Connecticut. Three more mergers later Brenton Saunders, the recently installed CEO of Actavis, presided over the No. 3 U.S. health care deal of all time, according to data provider S&P Capital IQ.
基于加利福尼亚州的Irvine，Allergan是加拿大缬草制药国际的漫长敌意收购竞标的目标，由Activist Investor William Ackman提供支持。随着Allergan Ceo David Pyott Soath接受该交易，即使在11月17日提高了10.55份溢价，Actavis仍然可以获得10.55美元的溢价，即使在11月17日上涨5.3％，达到209.20美元。缬草首席执行官J. Michael Pearson说他不会提高200美元的份额。
要抵御缬草，Allergan一直在寻找合并合作伙伴。该公司花了几个月与罗利，北卡罗来纳州的萨利克斯制药，但在萨利克斯会计修订之后，努力落下了暴露的荒谬销售。Actavis是另一个潜在的合作伙伴，任何交易在Allergan的12月股东大会之前结束。“David [Pyott]和我今年夏天迟到了，我提到如果他正在寻找一个合作伙伴，我们在Actavis有很多重叠。他后来联系了，“Sacavis Ceo Saunders说。
合并后的业务,预计23美元ion in revenue for 2015, with cost savings of $1.8 billion. Advising Actavis on the deal, which still needs shareholder consent and antitrust approval in the U.S. and the European Union, was JPMorgan Chase & Co., which is due to earn an estimated $73 million; Bank of America Merrill Lynch, Credit Suisse Group and Goldman Sachs Group represented Allergan, will share $119 million.
For deal enthusiast Saunders, 43, this was the latest in a $99 billion string of acquisitions under his watch. He came to Actavis in February 2014 via the $25 billion acquisition of New York–based drugmaker Forest Laboratories, where he had just been appointed CEO. According to CRT Capital’s Chiang, Saunders got the job with a firm push from Ackman rival Carl Icahn, who had made Forest the target of proxy battles since becoming a major shareholder in 2009. The merger saw Saunders take charge of Actavis from Paul Bisaro, who was named executive chairman. Before joining Forest, Saunders was CEO of Bausch & Lomb; in August 2013 he pulled off the $8.6 billion sale of the eye care giant, working with its owner, private equity firm Warburg Pincus, to none other than Valeant.
在Saunders在Actavis拿下掌舵之前不久，该公司已经抢购了华纳·奇尔科斯 - 另一个以前的缬友目标 - 以92亿美元的反转，获得了爱尔兰税收性的税收。该地质在森林收购的进一步税收折扣中得到了退还。Actavis Saw Forest作为获取名牌的机会，以获得更大的玩家是缠绕的，如抗抑郁的Celexa。“我们不得不在交易中争夺几个演示者，”纽约精品投资银行Greenhill＆Co.的董事总经理Ashish Contractor表示，他们在合并中向Actavis提供了建议。警惕留市的商业银行以免谈判泄漏的消息，该公司悄然关闭了总统日的森林。
Top 10 Deals of 2014
- Kinder Morgan全部进来
- 康卡斯特面临屏幕测试
- Actavis实现了更大的Pharma野心
- Medtronic，Covidien Home绑在一起
- LAFARGE和HOLCIM倒了
- 阿里巴巴使用纽约证券交易所首次亮相
- Facebook的数据驱动接管WhatsApp
- ALTECE转变纸质利润
- Eurobank Ergasias Spearheads a Greek Banking Revival
- 债券问题提升U.K.的人民币交易信誉
Follow Anne Szustek on Twitter at@the59thStBridge。